The results of the recent CANTOS trial showed neutralizing IL-1β with a human monoclonal antibody leads to dose-dependently reduction in C-reactive protein (CRP) and IL-6 levels (43% reduction from the baseline) in patients with previous myocardial infarction, providing support for the inflammatory basis of athero-thrombosis in humans [71]. Here, CRP is linked to myocardial infarction.